←
Timothy Chan6,683 posts
Timothy Chan avatar✓

Timothy Chan ✓

@GeneCollector

Enterprise Chair, Cancer Sciences, Cleveland Clinic Health System, @ClevelandClinic; Professor of Medicine; fan of tennis, coral reefs, Legos; views my own

◷ Joined April 2017▧ 429 Photos and videos
Michel Doepke avatar
⟳ Timothy Chan retweeted
Michel Doepke@doepke_michel·Nov 12

I'd like to share this slide again. We've reached a point where the treatment of PDAC is undergoing a paradigm shift. We're only at the beginning - and we'll see even better data. In my opinion, combination studies are the way forward. Time will tell. $TNGX $RVMD $ERAS

Post attachment
Razelle Kurzrock, MD avatar
⟳ Timothy Chan retweeted
Razelle Kurzrock, MD@Dr_R_Kurzrock·Oct 24

Hear ye hear ye!! New pembrolizumab TMB tumor-agnostic threshold is 13 rather than 10. 🔥 Our data suggests it is 16 mut/mb (best threshold) Data coming soon! Responses can be phenomenal. I have patients who went from “next step hospice” to “CR ongoing for years— aka cured”

Post attachment
Midwest vs. The Rest avatar
⟳ Timothy Chan retweeted
Midwest vs. The Rest@midwestern_ope·Oct 24

Driving in Detroit is fun until you realize you needed to be in a different lane three miles ago and now you’re entering Canada

Post attachment
Nieves Martinez Lago MD PhD avatar
⟳ Timothy Chan retweeted
Nieves Martinez Lago MD PhD@DraMartinezLago·Oct 23

#ESMO26 🚀 RASolute 302 | Phase III 👥 500 pts | Previously treated mPDAC 💊 Daraxonrasib (RAS(ON) inhibitor) vs chemo 📈 OS: 13.2 vs 6.7 mo (HR 0.40) 🧬 OS benefit by RAS genotype: 🔹 G12D: HR 0.49 🔹 G12V: HR 0.32 🔹 G12R: HR 0.61 📊 PFS: HR 0.55 (BICR) 🎯 ORR: 32% vs 11% 💡 new SOC! @OncoAlert

Post attachmentPost attachmentPost attachmentPost attachment
Razelle Kurzrock, MD avatar
⟳ Timothy Chan retweeted
Razelle Kurzrock, MD@Dr_R_Kurzrock·Oct 11

Amazing. 🎯🔥We published this in 2023. 2.5 years later, May 2026, Japan gives world-first tumor-agnostic approval to alectinib for ALK fusion solid cancers

Post attachment
Matthew Kirshner avatar
⟳ Timothy Chan retweeted
Matthew Kirshner@MattyKirsh·Sep 28

Just the Editor-in-Chief of Nature advising scientists not to share their data and findings with external AI model companies.

Post attachmentPost attachment
Nikon Small World avatar
⟳ Timothy Chan retweeted
Nikon Small World@NikonSmallWorld·Sep 25

Everyone knows the mitochondria is the "powerhouse of the cell." But have you seen how beautifully its movement was captured by Dr. Patrick C. Hickey in this 5th place #SmallWorldInMotion winning video? 🏆 Now you have! bit.ly/3TgEWKn

0:57
Stanislav (Stas) Lazarev, MD avatar
⟳ Timothy Chan retweeted
Stanislav (Stas) Lazarev, MD@StasLazarev·Sep 25

⚡️Randomized phase III trial of adjuvant RT vs observation after gross total resection of WHO grade 2 meningioma just got published ⚡️ 157 pts ➡️ 78 RT ➡️ 79 observation ➡️ RT = 60 Gy/30 fx ➡️ median follow-up ~5 years At ~5 years: 🔁 Recurrence: 14% with RT vs 30% with obs 📈 5-year DFS: 80% vs 64% ❗️There was no difference in OS, but only 13 pts died in the entire trial, and 95% CI was huge 0.27-3.05. So one really can't tell from this study whether RT improves, worsens, or has no effect on OS. It was simply far too underpowered for that endpoint. Could salvage tx in the obs arm attenuate OS difference? Possibly. More pts in the obs arm required 2nd-line tx (20% vs 10% with RT), but ROAM doesn't quite establish that salvage tx explains the lack of OS difference - it is a plausible interpretation, but not a proven conclusion. ✔️QoL and neurocognitive outcomes were similar which is reassuring, but QoL data were available in only 38% of pts at 5 yrs, while by 2 yrs ~45% of neurocognitive data were missing. So there is simply too much missing data to conclude that either strategy leads to better or worse QoL or neurocognitive function. After all, if a tumor recurs and a pt needs salvage surgery and/or RT, it is plausible that QoL could worsen simply from the burden of additional tx 🎯 My take-home: RT reduces the risk of recurrence after GTR of grade 2 meningioma But, just like in breast, prostate, and other cancers with otherwise favorable prognosis, there will be a sizable group of pts who would never recur even without additional tx. Here, about 70% of pts observed had not recurred at ~5 years. So, as with most things in oncology, selection is really the 🔑 I’d particularly consider RT in younger patients and those with higher-risk clinical and/or molecular features and in cases where postop 68Ga-DOTATATE PET detects residual disease that may not be clearly visible on MRI.

Post attachment
Timothy Chan avatar
Timothy Chan@GeneCollector·Sep 25

Well, being delayed at La Guardia isn’t so bad now. If we had the new LGA when I was living in NY, quality of life would have been measurably higher

Adam Rochussen avatar
⟳ Timothy Chan retweeted
Adam Rochussen@AdamRochussen·Sep 25

In 1980, 21% of NIH-funded principal investigators were under age 35. By 2015, this proportion was 3%. The dramatic ageing of independent scientists is bad because old people are simply worse at science than young people. Latest meta-scientific deep-dive from me 🧵 ⬇️

0:06
HHMI avatar
⟳ Timothy Chan retweeted
HHMI@hhmi_science·Sep 19

Lighting up your screen: a larval zebrafish's cellular activity. Developed by researchers at our Janelia Research Campus, WHaloCaMP is a biosensor that detects calcium signals & offers a window into how cells & organs work together. 🎥 Helen Farrants, HHMI JRC

0:04